GlassScriptPhysician profile
Walter Matheny
NPI 1053911339
$783.63
in general payments reported to CMS, 2019-2025
12 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $61.93 · 2023: $118 · 2024: $334 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $213.38 | 2022-2025 | Savvywire, Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Stryker Corporation | $165.51 | 2024-2025 | Flowtriever, Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Inari Medical, INC. | $131.80 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $87.74 | 2023-2025 | Icefx Cryoablation System, Cryoablation Needles |
| Terumo Medical Corporation | $47.38 | 2025 | Azur Cx Detachable, Angio-Seal |
| Seagen INC. | $27.18 | 2023 | Adcetris |
| Trisalus Life Sciences, INC. | $23.03 | 2024 | Trinav Infusion System |
| Eisai INC. | $18.34 | 2024 | |
| Merck Sharp & Dohme LLC | $18.20 | 2024 | Keytruda |
| Azurity Pharmaceuticals, INC. | $17.37 | 2024 | Vivimusta |
| Alexion Pharmaceuticals, INC. | $17.30 | 2024 | Ultomiris |
| Agios Pharmaceuticals, INC. | $16.40 | 2024 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Matheny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.